Announcement of identification of the highly potent small molecule drug candidates targeting a novel kinase and decision of pursuing clinical development

On July 31, 2013 OncoTherapy Science reported that OncoTherapy has identified novel highly potent small molecule drug candidates for a novel kinase target and has decided to pursue clinical development (Press release OncoTherapy Science, JUL 31, 2013, View Source [SID:1234500750]). OncoTherapy has been developing small molecule inhibitors for several novel targets that had been discovered with the genome-wide expression profile analysis. Recently, OncoTherapy has identified novel small molecule compounds including OTS964 that specifically inhibit a novel kinase target and decided to pursue clinical development of them. This novel kinase is totally different from MELK (maternal embryonic leucine zipper kinase) for which US Food and Drug Administration (FDA) has already accepted Phase I clinical trial with the MELK inhibitor OTS167. This novel kinase is not expressed in the important vital organs at all, but highly up-regulated in various types of cancers such as the lung cancer, and plays an important role in tumor growth. These highly potent small molecule drug candidates including OTS964 which specifically inhibit the novel kinase showed striking anti-tumor effects against human lung and bladder cancers in animal studies, and are therefore expected to show potent anti-tumor effects in human. This drug candidate is our second small molecule drug candidate, following OTS167. OncoTherapy does make every effort to develop this candidate, based on our mission "To develop anti-cancer medicine and cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer". The impact of this identification on our consolidated business performance is immaterial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!